| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.127 |
| Chemical and physical data | |
| Formula | C12H16N2O3 |
| Molar mass | 236.271 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Cyclobarbital, cyclobarbitol or cyclobarbitone (brand name Phanodorm) is a barbiturate derivative developed in the early 1920s in Germany.
It was available in Russia until 2019, marketed and distributed as Reladorm, a fixed-dose combination pairing 100 mg cyclobarbital and 10 mg diazepam (a benzodiazepine anxiolytic, muscle relaxant, and anticonvulsant) indicated for treating insomnia before it was discontinued in 2019.
| Alcohols | |
|---|---|
| Barbiturates |
|
| Benzodiazepines |
|
| Carbamates | |
| Flavonoids |
|
| Imidazoles | |
| Kava constituents | |
| Monoureides | |
| Neurosteroids |
|
| Nonbenzodiazepines |
|
| Phenols | |
| Piperidinediones | |
| Pyrazolopyridines | |
| Quinazolinones | |
| Volatiles/gases |
|
| Others/unsorted |
|